Callen-Lorde Community Health Center
New York, 10011, United States
NCT Number: NCT02037594
This study identifies social and behavioral factors likely to influence PrEP acceptability and adherence among men who have sex with men (MSM), and collaborates with a community health center to evaluate a two-stage intervention to improve PrEP decision-making, as well as persistence and adherence for those who chose to take PrEP.
Looking for future studies?
Notify Me18 year and older
Male
Interventional
Not applicable
New York, 10011, United States
Pre-exposure prophylaxis (PrEP) refers to daily or intermittent oral administration of antiretroviral drugs designed to protect high-risk HIV-negative individuals from infection. In order for PrEP to become an effective prevention tool, three critical factors must be addressed: a) acceptability, i.e., individuals who would benefit from PrEP must know about it and be willing to take it; b) adherence, i.e., individuals who choose to PrEP as a prevention strategy must take the pills as prescribed; and c) implementation, i.e., processes and protocols must be developed to allow for the integration of PrEP delivery and programs into real world settings in a way that is feasible, scalable, and realistic. This project has three specific aims: 1) Identifying social and behavioral factors that are likely to influence PrEP implementation, acceptance, and use/adherence by men who have sex with men (MSM) in NYC, including factors at individual-, community-, and organizational-levels; 2) Examining social and behavioral factors associated with disparities in access to prevention and care services among MSM in NYC that might directly impact PrEP implementation programs and policies; and 3) Evaluating an intervention in which PrEP is introduced, provided, and supported as part of a prevention package delivered in an community health center. The project has the potential to exert a sustained and powerful influence not only on the effectiveness of PrEP interventions for MSM, but also on dissemination and scalability of a targeted intervention within community-based settings and in a manner that reduces disparities in access and maximizes cultural competence and acceptability.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.
This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.
Standard of Care Information about PrEP
Standard of care information and instruction about PrEP adherence.
Time frame: BL through 3-months
Whether or not the patient decides to take PrEP
Time frame: BL through 12-months
Whether or not patients who decide to take PrEP persist with the medication for the duration of the study.
Time frame: BL through 12 months
Biological measure of medication adherence using dried blood spots, and self-report measure of adherence using VAS.
Time frame: BL through 12-months
Measured through STI testing and self-report.
Hunter College of City University of New York
Other
Acronym: SPARK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05664802
Acquired Immunodeficiency Syndrome, Behavior
Flagstaff, Arizona, United States
View Trial DetailsNCT07553052
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Surakarta, Central Java, Indonesia
View Trial DetailsNCT05423418
AIDS Virus, Acquired Immunodeficiency Syndrome
Silver Spring, Maryland, United States
View Trial DetailsNCT06783192
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
South Miami, Florida, United States
View Trial Details